Skip to main content

Chengbao Liu, MD

Board Certifications

Anatomic and Clinical Pathology


Oncologic Surgical Pathology, Gynecologic


Immunohistochemistry, Surgery Center Services, Women's Health


  • Fellowship – Oncologic Surgical Pathology, Memorial Sloan Kettering Cancer Center, New York
  • Residency – Chief Resident, Anatomic and Clinical Pathology, Stony Brook University Medical Center, Stony Brook, New York
  • Medical School – China Medical University, Shenyang, China
  • Dr. Liu is the vice-chair of the Department of Pathology at Dallas Medical Center. He has published more than 30 peer-reviewed articles and abstracts.
  • Joined ProPath in 2018

Peer-Reviewed Articles

  1. Liu C, Dillon J, Beavis AL, Liu Y, Lombardo K, Fader AN, Hung CF, Wu TC, Vang R, Garcia JE, Xing D. Prevalence of somatic and germline mutations of fumarate hydratase in uterine leiomyomas from young patients. Histopathology. September 2019. doi:10.1111/his.14007.

  2. Xing D, Berrebi AA, Liu C, Richmond A, Vang R, Ronnett BM. An epithelioid smooth muscle neoplasm mimicking a signet ring cell carcinoma in the ovary. Int J Gynecol Pathol. 2019;38(5):464-469.

  3. Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H. Loss of nuclear localized parathyroid hormone-related protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling. Clin Can Res. 2018; 24(24):6355-6366.

  4. Zheng G, Richmond A, Liu C, Berrebi A, Pallavajjala A, Haley L, Stone RL, McCarthy E, Vang R, Xing D. Clinicopathologic features and genetic alterations of a primary osteosarcoma of the uterine corpus. Int J Gynecol Pathol. 2018 Apr 6. [Epub ahead of print].

  5. Lockney DT, Jia AY, Lis E, Lockney NA, Liu C, Hopkins B, Higginson DS, Yamada Y, Laufer I, Bilsky M, Schmitt AM. Myositis following spine radiosurgery for metastatic disease: a case series. J Neurosurg Spine. 2018;28(4):416-421.

  6. Yang N, Leung ELH, Liu C, et al. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma. Oncogene. 2017; 36(35):4997-5005.

  7. Peck AR, Girondo MA, Liu C, et al. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Mod Pathol. 2016;29(10):1143-1154.

  8. Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene. 2016;35(11):1373-1385.

  9. Hu ZI, Liu C, Fisher PR, Cohen JA. Intracystic papillary carcinoma of the breast in a male patient. Rare Tumors. 2016;8(1):6050.

  10. Wilson C, Lin JE, Li P, Snook AE, Schulz S, Rui H, Sato T, Liu C, Girondo MA, Gong JP, Hyslop T, Waldman SA. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2328-2337.

  11. Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene. 2014;33(17):2215-2224.

  12. Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Balckmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H. STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol. 2013;182(6):2264-2275.

  13. Yang N, Liu C, Peck AR, et al. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Res. 2013;15(5):R73.

  14. Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J, Neilson LM, Rui H. Global profiling of prolactin-modulated transcripts in breast cancer in vivo. Mol Cancer. 2013;12(1):59.

  15. Lin WC, Rajbhandari N, Liu C, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 2013;73(6):1821-1830.

  16. Peck AR, Witkiewicz AK, Liu C, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res. 2012;14(5):R130.

  17. Huangfu WC, Qian J, Liu C, et al. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene. 2012;31(2):161-172.

  18. Peck AR, Witkiewicz AK, Liu C, et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol. 2011;29(18):2448-2458.

  19. Zhang Q, Sakamoto K, Liu C, et al. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Res. 2011;71(24):7513-7524.

  20. Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Res Treat. 2011;130(3):791-807.

  21. Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz AK, Dasgupta A, Hyslop T, Torhorst J, Bubendorf L, Haas P, Nevalainen MT, Sauter G, Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res. 2011;1(3):347-355.

  22. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen K, Knudsen E. RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle. 2010;9(20):4153-4163.

  23. Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Nielson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H. Prolactin inhibits expression of the proto-oncogene BCL6 in breast cancer through a Stat5a-dependent mechanism. Cancer Res. 2010;70(4):1711-1721.

  24. HuangFu WC, Qian J, Liu C, Rui H, Fuchs SY. Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling. Pigment Cell Melanoma Res. 2010;23(6):838-840.

  25. Johnson KJ, Peck AR, Liu C, et al. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol. 2010;177(6):2971-2983.

  26. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, Pestell RG, Sotgia F, Rui H, Lisanti MP. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther. 2009;8(11):1071-1079.

  27. Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Res. 2009;69(7):3165-3172.

  28. Baker JR, Liu C, Dong S, Pritchard DG. Endopeptidase and glycosidase activities of the bacteriophage B30 lysin. Appl Environ Microbiol. 2006;72(10):6825-6828.

  29. Thazhath R, Liu C, Gaertig J. Polyglycylation domain of β-tubulin maintains axonemal architecture and affects cytokinesis in Tetrahymena. Nat Cell Biol. 2002;4(3):256-259.


  1. Liu C, Harmon B, Shroyer K, Korman M, Hwang S, Pearl M, Henretta M, Tornos C. Monoclonal PAX-2 in mucinous ovarian tumors: a study of 59 cases of primary and metastatic tumors. Arch Pathol Lab Med. 2014; 138(9) e2:121-2.

  2. Liu C, Heimann A, Waltzer W, Wu S, Zawin M, Hwang S, Liu J. Positive margins in partial nephrectomy specimens do not predict recurrence. Mod Pathol. 2014;27(suppl 2s):246A.

  3. Liu C, Balakrishnan D, Heimann A, Birney L, Zee S, Tornos C, Singh M, Shroyer K, Liu J. ThinPrep CytoLyt fixation has no effect on ER and cytokeratin staining on normal breast tissue. Mod Pathol. 2014;27(suppl 2s):507A.

  4. Liu C, Heimann A, Waltzer W, Liu J. Renal percutaneous needle core versus fine needle aspiration, or both? Mod Pathol. 2013;26(suppl 2s):231A.